Form 4: Verrica Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


Joe Bonaccorso, Chief Commercial Officer of Verrica Pharmaceuticals, sold shares to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Summary

  • Joe Bonaccorso, the Chief Commercial Officer of Verrica Pharmaceuticals, sold shares of common stock on August 26 and 27, 2024.
  • These sales were to cover statutory tax withholding obligations related to the settlement of restricted stock units, as mandated by the company's 2018 equity incentive plan.
  • On August 26, 2024, 24,709 shares were sold at a weighted average price of $2.66, with prices ranging from $2.53 to $2.83.
  • On August 27, 2024, 8,993 shares were sold at a weighted average price of $2.46, with prices ranging from $2.40 to $2.53.
  • Following these transactions, Bonaccorso directly owns 73,114 shares of Verrica Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale to cover taxes) and doesn't contain any information that would significantly impact sentiment positively or negatively.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation and equity plans. This transaction is not necessarily indicative of the executive's view of the company's future prospects.

Key Dates

DateDescription
08/26/2024Sale of 24,709 shares of common stock at a weighted average price of $2.66.
08/27/2024Sale of 8,993 shares of common stock at a weighted average price of $2.46.
08/28/2024Date of Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.